全球膽管癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計膽管癌治療市場規模將從 2025 年的 2.6917 億美元成長到 2034 年的 5.3094 億美元，並預計從 2026 年到 2034 年將以 7.84% 的複合年成長率成長。

由於膽管癌（膽管細胞癌）發生率低且診斷往往較晚，其治療市場歷來小規模。然而，隨著標靶治療和免疫腫瘤藥物的出現，該領域再次受到關注。儘管化療多年來一直是標準治療方法，但基因組分析發現了可治療的突變（例如IDH1和FGFR2融合），從而推動了標靶抑制劑的研發和特定適應症的核准。腫瘤中心分子檢測的普及提高了可治療亞型的診斷率，擴大了目標患者群體，也吸引了投資者的目光。

精準腫瘤學的進步、標靶藥物的監管核准以及分子診斷的普及是推動成長要素。在腫瘤網路和患者權益組織的推動下，全球臨床試驗活動顯著增加。這加速了適應症的擴展以及特定族群的仿單標示外用藥。伴隨診斷和基於生物標記的患者招募提高了研發效率，即使患者絕對數量較少，市場也正向高附加價值的專科療法轉型。

未來前景謹慎但樂觀。持續發現可治療的突變以及與免疫療法的聯合策略有望拓展治療選擇並提高存活率。市場擴張取決於基因組檢測的廣泛應用、昂貴標靶藥物的報銷政策以及後期臨床試驗的成功，這些試驗需證實藥物的持續療效。由於該疾病罕見，預計患者單次治療費用高昂，標靶治療之間存在競爭，因此需要重視伴隨診斷和真實世界數據以促進藥物推廣。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球膽管癌治療市場：依標靶治療分類

• 市場分析、洞察與預測
• 培米加替尼
• Infigratinib（3期試驗）
• Ivosidenib（3期試驗）
• 免疫療法（Pembrolizumab（3期臨床試驗））
• 其他

第5章 全球膽管癌治療市場：依應用分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 其他

第6章：全球膽管癌治療市場：依適應症分類

• 市場分析、洞察與預測
• 肝內膽管癌
• 肝外膽管癌

第7章 全球膽管癌治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球膽管癌治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Johnson & Johnson Private Limited
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • AbbVie Inc
  • Novartis AG
  • Fresenius Kabi AG
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Intercept Pharmaceuticals
  • Kyowa Kirin Co. Ltd
  • Delcath Systems Inc

The Bile Duct Cancer Drug Market size is expected to reach USD 530.94 Million in 2034 from USD 269.17 Million (2025) growing at a CAGR of 7.84% during 2026-2034.

The bile duct (cholangiocarcinoma) drug market has historically been small due to disease rarity and late-stage diagnosis, but it has seen renewed interest as targeted therapies and immuno-oncology agents emerge. Traditional chemotherapy remained the standard for years, but genomic profiling revealed actionable mutations (IDH1, FGFR2 fusions, etc.), prompting development of targeted inhibitors and niche approvals. Increased molecular testing at oncology centers has elevated diagnosis of targetable subtypes, expanding addressable patient populations and investor interest.

Primary growth drivers are advances in precision oncology, regulatory approvals of targeted agents, and expanding access to molecular diagnostics. Clinical trial activity has increased globally, supported by oncology networks and patient advocacy; this has accelerated label expansions and off-label use in select populations. Companion diagnostics and biomarker-driven enrollment have made development more efficient despite small absolute patient numbers, shifting the market toward high-value, specialized therapies.

Future prospects are cautiously optimistic: continued identification of actionable mutations and combination strategies with immunotherapies could broaden therapeutic options and improve survival. Market expansion depends on wider availability of genomic testing, reimbursement policies for expensive targeted agents, and successful late-stage trials demonstrating durable benefit. Given the orphan nature of the disease, expect high per-patient pricing, rising competition among targeted therapies, and an emphasis on companion diagnostics and real-world evidence to support uptake.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Targeted Therapy

• Pemigatinib
• Infigratinib (Phase 3)
• Ivosidenib (Phase 3)
• Immunotherapy (Pembrolizumab (Phase 3))
• Others

By Application

• Hospitals
• Clinics
• Others

By Disease Indication

• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Johnson Johnson Private Limited, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline plc, AbbVie Inc, Novartis AG, Fresenius Kabi AG, Eli Lilly and Company, F HoffmannLa Roche Ltd, Intercept Pharmaceuticals, Kyowa Kirin Co Ltd, Delcath Systems Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BILE DUCT CANCER DRUG MARKET: BY TARGETED THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Targeted Therapy
• 4.2. Pemigatinib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Infigratinib (Phase 3) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Ivosidenib (Phase 3) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunotherapy (Pembrolizumab (Phase 3)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BILE DUCT CANCER DRUG MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BILE DUCT CANCER DRUG MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Indication
• 6.2. Intrahepatic Bile Duct Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Extrahepatic Bile Duct Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BILE DUCT CANCER DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BILE DUCT CANCER DRUG MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Targeted Therapy
  • 8.2.2 By Application
  • 8.2.3 By Disease Indication
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Targeted Therapy
  • 8.3.2 By Application
  • 8.3.3 By Disease Indication
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Targeted Therapy
  • 8.4.2 By Application
  • 8.4.3 By Disease Indication
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Targeted Therapy
  • 8.5.2 By Application
  • 8.5.3 By Disease Indication
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Targeted Therapy
  • 8.6.2 By Application
  • 8.6.3 By Disease Indication
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BILE DUCT CANCER DRUG INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Johnson & Johnson Private Limited
  • 10.2.2 Mylan N.V
  • 10.2.3 Teva Pharmaceutical Industries Ltd
  • 10.2.4 Sanofi
  • 10.2.5 Pfizer Inc
  • 10.2.6 GlaxoSmithKline Plc
  • 10.2.7 AbbVie Inc
  • 10.2.8 Novartis AG
  • 10.2.9 Fresenius Kabi AG
  • 10.2.10 Eli Lilly And Company
  • 10.2.11 F. Hoffmann-La Roche Ltd
  • 10.2.12 Intercept Pharmaceuticals
  • 10.2.13 Kyowa Kirin Co. Ltd
  • 10.2.14 Delcath Systems Inc